US Regulators Approve Moderna Flu Vaccine

The U.S. Food and Drug Administration (FDA) has approved Moderna's new influenza vaccine, marking a significant development in flu prevention options. This approval comes nearly six months after the FDA initially rejected the company's application for review. The new vaccine expands the portfolio of available flu vaccines for the upcoming season and offers healthcare providers and patients an additional option for annual influenza immunization. Moderna's entry into the flu vaccine market represents continued innovation in vaccine development and may increase competition among manufacturers. For Puerto Rico residents, this approval means greater vaccine availability and choice when preparing for seasonal flu protection.